Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
11/30/2012
Trade Name:
Invirase
Generic Name or Proper Name (*):
saquinavir
Indications Studied:
Treatment of HIV infection in combination with ritonavir
Label Changes Summary:
The safety and activity of saquinavir have been evaluated in 68 pediatric patients 4 months -< 16 years treated with Invirase boosted with either ritonavir or with lopinavir/ritonavir in 2 clinical trials. Steady state saquinavir exposures observed in pediatric trials were substantially higher than historical data in adults where dose- and exposure-dependent QTc and PR prolongation were observed. Pediatric dose recommendations that are both reliably effective and below thresholds of concern with respect to QT and PR prolongation could not be determined. Information on clinical studies, and pharmacokinetics
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B,P
Sponsor:
Hoffman- LaRoche
Pediatric Exclusivity Granted Date:
10/26/2010
NNPS:
FALSE'
Therapeutic Category:
Antiviral
-
-